Holen Sie sich die Stockscreener-App
0.1475
52.62%
-0.1638
Handel nachbörslich:
.15
0.0025
+1.69%
Schlusskurs vom Vortag:
$0.3113
Offen:
$0.16
24-Stunden-Volumen:
275.59K
Relative Volume:
0.05
Marktkapitalisierung:
$718.83K
Einnahmen:
-
Nettoeinkommen (Verlust:
$-21.33M
KGV:
-0.0013
EPS:
-113.7479
Netto-Cashflow:
$-9.12M
1W Leistung:
-73.13%
1M Leistung:
-77.17%
6M Leistung:
-89.46%
1J Leistung:
-96.18%
1-Tages-Spanne:
$0.13
$0.16
1-Wochen-Bereich:
$0.13
$0.555
52-Wochen-Spanne:
$0.13
$4.20
Zyversa Therapeutics Inc Stock (ZVSA) Company Profile
Firmenname
Zyversa Therapeutics Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie ZVSA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ZVSA
Zyversa Therapeutics Inc
|
0.1475 | 3.12M | 0 | -21.33M | -9.12M | -113.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Zyversa Therapeutics Inc Aktie (ZVSA) Neueste Nachrichten
Is ZyVersa Therapeutics Inc. a good long term investmentTremendous gains - jammulinksnews.com
What drives ZyVersa Therapeutics Inc. stock priceOutstanding capital growth - jammulinksnews.com
ZyVersa Therapeutics Inc. Stock Analysis and ForecastPhenomenal wealth increase - jammulinksnews.com
What analysts say about ZyVersa Therapeutics Inc. stockSkyrocketing profit margins - jammulinksnews.com
ZyVersa Therapeutics CEO Issues Mid-year Shareholder Letter - GlobeNewswire
ZyVersa secures $12 million in financing to advance kidney disease trials - Investing.com
ZyVersa Therapeutics Updates Shareholders on Key Developments and R&D Milestones in Mid-Year Letter - Nasdaq
ZyVersa Therapeutics Raises $12M to Accelerate Breakthrough Kidney and Inflammatory Disease Treatments - Stock Titan
ZVSA’s Market Whiplash: -93.65% YTD Decline, -52.27% Plunge in 30 Days - investchronicle.com
Why ZyVersa Therapeutics Inc. stock attracts strong analyst attentionFree Best Performing Stock Suggestions - Newser
ZyVersa Therapeutics to be delisted from Nasdaq, trading to move to OTC market - Investing.com India
ZyVersa Therapeutics Faces Nasdaq Delisting, Plans Pink Market Move - TipRanks
ZyVersa Therapeutics to be delisted from Nasdaq, trading to move to OTC market By Investing.com - Investing.com South Africa
How ZyVersa Therapeutics Inc. stock performs during market volatilityWatchlist Winner Update - Newser
What makes ZyVersa Therapeutics Inc. stock price move sharplyFree Stock Selection with 300% Return - Newser
ZyVersa Therapeutics (NASDAQ:ZVSA) Rating Increased to Hold at Wall Street Zen - Defense World
ZyVersa Therapeutics (ZVSA) Stock Price, News & Analysis - MarketBeat
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator?? VAR 200 in A Patient with ApoCII Amyloidosis - MarketScreener
Why Did ZyVersa Therapeutics Plunge 10% Despite Funding Boost? - AInvest
ZyVersa Therapeutics (NASDAQ:ZVSA) Shares Up 17.4% – Time to Buy? - Defense World
ZyVersa Therapeutics Supports FDA-Authorized Emergency - GlobeNewswire
ZyVersa Secures $2 Mln Through Warrant Inducement Deal With Institutional Investor - Nasdaq
ZVSA’s Stock Journey: What Investors Need to Know About ZyVersa Therapeutics Inc’s Performance - investchronicle.com
Why Did ZyVersa Therapeutics Stock Shoot Higher On Tuesday? - Benzinga
Intensity Therapeutics Inc’s Shares Reel: -85.34% Quarterly Revenue Decline Amid 7.38M Market Cap - investchronicle.com
ZyVersa announces warrant inducement transaction for $2M in gross proceeds - TipRanks
ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds - GlobeNewswire
Biotech ZyVersa Raises $2M in Strategic Warrant Deal to Advance Drug Development Pipeline - Stock Titan
Astria Therapeutics Inc (ATXS) Stock: Uncovering 52-Week Market Trends - investchronicle.com
ZyVersa’s VAR 200 approved for emergency use in rare kidney disease - Investing.com
ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator™ VAR 200 in a Patient with ApoCII Amyloidosis - The Manila Times
FDA Grants Emergency Access to ZyVersa's VAR 200 Drug for Ultra-Rare Kidney Disease Treatment - Stock Titan
ZyVersa Therapeutics (ZVSA) Launches Phase 2a Study for DKD Treatment | ZVSA Stock News - GuruFocus
ZyVersa begins patient recruitment for kidney disease drug trial - Investing.com
ZyVersa begins patient recruitment for kidney disease drug trial By Investing.com - Investing.com South Africa
ZyVersa Therapeutics (ZVSA) Secures Funding Deal to Advance Kidn - GuruFocus
ZyVersa enters $10 million share purchase agreement with WVH By Investing.com - Investing.com UK
ZyVersa Therapeutics announcs share purchase agreement for up to $10M - TipRanks
ZyVersa enters $10 million share purchase agreement with WVH - Investing.com
Critical Analysis: ZyVersa Therapeutics (NASDAQ:ZVSA) vs. Schrödinger (NASDAQ:SDGR) - Defense World
ZyVersa Therapeutics (NASDAQ:ZVSA) Upgraded at Wall Street Zen - Defense World
ZyVersa Therapeutics Stockholders Approve Key Proposals - TipRanks
Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World
At $0.65 Price, ZyVersa Therapeutics Inc (ZVSA) Is Sitting And Waiting - Stocksregister
ZyVersa Therapeutics Reports Q1 2025 Financial Results - TipRanks
Finanzdaten der Zyversa Therapeutics Inc-Aktie (ZVSA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):